Cd37 immunotherapeutic combination therapies and uses thereof

Details Cd37 immunotherapeutic combination therapies and uses thereof Cd37 immunotherapeutic combination therapies and uses thereof

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 31/436 (2006.01) C07K 16/28 (2006.01)

Patent

CA 2743487

The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phos-phatidylinositol 3-kinase (PI3K) inhibitors (such as p110?-specific inhibitors or the like), which can be done concurrently or se-quentially, to treat or prevent a B cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like.

La présente invention concerne des procédés pour utiliser des molécules de liaison spécifiques de CD37 (telles quun SMIP ou anticorps spécifique de CD37) en combinaison avec des inhibiteurs de mTOR (tels que la rapamycine et des dérivés ou analogues de celle-ci) ou des inhibiteurs de phosphatidylinositol-3-kinase (PI3K) (tels que des inhibiteurs spécifiques de p110 ou similaire), qui peuvent être conduits simultanément ou séquentiellement, pour traiter ou prévenir une maladie hyperproliférative associée aux lymphocytes B, telle quun lymphome, un carcinome, un myélome, ou similaire.

Affiliated with

Also associated with

Rating

Cd37 immunotherapeutic combination therapies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cd37 immunotherapeutic combination therapies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cd37 immunotherapeutic combination therapies and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2067807